Effectiveness of rituximab in severe Wegener's granulomatosis: report of two cases and review of the literature.
We hereby describe the satisfactory evolution of rituximab treatment in two patients with Wegener's granulomatosis (WG). Rituximab was indicated for refractoriness to standard treatment in one case and life-threatening myelotoxicity due to alkylating agents in the other. A brief review of previous experience with the use of rituximab in the treatment of WG is presented.
Oristrell
Joaquim
J
Internal Medicine Service, Hospital de Sabadell, Corporació Parc Taulí, Universitat Autònoma de Barcelona (UAB), Spain.
Bejarano
Guillermina
G
Jordana
Rosa
R
Monteagudo
Manuel
M
Marí
Begoña
B
Casanovas
Arnau
A
Tolosa
Carles
C